Accumulating evidence has suggested that targeting TFEB to regulate ALP is a promising approach to developing new drugs to treat neurodegenerative disorders including AD (Chandra, Jana, & Pahan, 2018; Chauhan et al., 2015; Martini‐Stoica et al., 2018; Polito et al., 2014; Wang et al., 2016; Xiao et al., 2014, 2015). This evidence concerns the gene TFEB and Alzheimer disease.